New partnership seeks to treat cause of diabetes
The Broad Institute and Novo Nordisk have formed a research partnership.
Tackling Diabetes From Every Angle
Physicians, geneticists, chemists, and other researchers in Broad’s Diabetes Research Group are working together and taking multiple approaches to improve treatment for patients with diabetes.
Massive NIH–industry project opens portals to target validation
Five years in, the US$360 million Accelerating Medicines Partnership is yielding tools to speed up drug discovery for rheumatoid arthritis, lupus, diabetes, Alzheimer disease and Parkinson disease.
DNA analysis identifies five subtypes of type two diabetes
The genomic study brings us closer to precision medicine for type 2 diabetes
Type 2 diabetes: Five genetic ‘clusters’ may explain evolution
La Medicina Personalizada para la diabetes tipo 2, cada vez más cerca
Más cerca de la medicina de precisión para la diabetes tipo 2
Una nueva clasificación de la diabetes tipo 2 facilitará la medicina ‘a la carta’
Turning risk association to biological insight in type 2 diabetes
Following up on findings from genome-wide association studies, researchers identify two mechanisms by which disruptions in the gene SLC16A11 may play a role in type 2 diabetes.